The high price of anticancer drugs: origins, implications, barriers, solutions.
about
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.Integrins as Therapeutic Targets: Successes and Cancers.ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of anti-neoplastic medicines in countries outside of Europe.Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan.Targeting the value of targeted therapy.Rituximab biosimilar evaluated by network meta-analysis.Using single-cell multiple omics approaches to resolve tumor heterogeneity.Does the oncology community have a rejection bias when it comes to repurposed drugs?Fishing for answers in precision cancer medicine.A further strategy to combat the high price of anticancer drugs.Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Value-based procurement of prostheses for total knee replacement.Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan.Endophytic Fungi-Alternative Sources of Cytotoxic Compounds: A Review.Developments of Cyanobacteria for Nano-Marine Drugs: Relevance of Nanoformulations in Cancer Therapies.Precision oncology: separating the wheat from the chaff
P2860
Q38608747-33B19110-AE1D-4705-B503-1A6B60AA0252Q39431314-3022EE50-92B6-4E4A-9005-F93FEFC82511Q41670949-603F9805-A866-4452-ADDF-37B2857226A4Q42693274-8D78114D-2305-4AB5-8513-76A2BCEF2EBEQ47097742-AFCEEB9F-14B1-40A7-8EF5-E539A354FB87Q47120188-8CCD68B6-799D-4BF9-9B16-8C093F9D0E06Q47151262-DE2472A4-9DC8-48C8-B50A-8EE730504022Q47236022-66896F66-AD8D-4A3F-9145-A3D3375396E1Q49884530-3B6CECE7-0A9B-4D21-A2E0-DBABEB40362BQ50061359-8420DDFE-ABA3-4803-B421-430FFF7D5244Q50599945-36E21C15-F493-440F-8B57-7400E17B1447Q52668760-0FED20C5-73A7-445E-849E-FACE2BEEAD93Q54977541-333401D8-DB35-4122-AA9C-8181C52B2DA3Q55262745-7BDDB535-CF47-4944-83D5-0CE278B7AE10Q55279429-0BCB2F39-42B3-4B2B-9845-EFF988A0509BQ55313088-C04EF72C-9482-45F6-9E01-93C21B2552E9Q55453641-B0F3E48E-6CFC-4D76-BA8E-F55DA6DF9B22Q58698377-6696F631-6025-45F4-A20D-AA54E7CCF482
P2860
The high price of anticancer drugs: origins, implications, barriers, solutions.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The high price of anticancer drugs: origins, implications, barriers, solutions.
@en
type
label
The high price of anticancer drugs: origins, implications, barriers, solutions.
@en
prefLabel
The high price of anticancer drugs: origins, implications, barriers, solutions.
@en
P2860
P1476
The high price of anticancer drugs: origins, implications, barriers, solutions.
@en
P2093
Kevin De Jesús
Sham Mailankody
P2860
P304
P356
10.1038/NRCLINONC.2017.31
P407
P50
P577
2017-03-14T00:00:00Z